tetherex.comBioTechFounded: 2002Funding to Date: $70.84MM
Developer of drugs for the treatment of inflammatory and thrombotic diseases. The company's treatment program is built around an antibody called SelK2 directed against the cell adhesion molecule P-Selectin Glycoprotein Ligand-1 (PSGL-1).
For more details on financing and valuation for Tetherex Pharmaceuticals, register or login.
Already registered? Click here to log in
To read this article and more news on Tetherex Pharmaceuticals, register or login.
Already registered? Click here to log in.
Forge and SharesPost have teamed up to provide you with an enhanced trading experience.